CA2354601A1 - Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males - Google Patents
Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males Download PDFInfo
- Publication number
- CA2354601A1 CA2354601A1 CA002354601A CA2354601A CA2354601A1 CA 2354601 A1 CA2354601 A1 CA 2354601A1 CA 002354601 A CA002354601 A CA 002354601A CA 2354601 A CA2354601 A CA 2354601A CA 2354601 A1 CA2354601 A1 CA 2354601A1
- Authority
- CA
- Canada
- Prior art keywords
- apomorphine
- hydrochloride
- administered
- erectile dysfunction
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
Abstract
A method of treating organic erectile dysfunction, particularly vasculogenic erectile dysfunction comprises administering to a male in need of such treatment a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt or pro-drug thereof.
Description
USE OF APOMORPHINE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF
ORGANIC
ERECTILE DYSFUNCTION IN MALES
This invention relates to medical methods of treatment. More particularly, the invention concerns the use of apomorphine for the treatment of organic erectile dysfunction in males, particularly vasculogenic erectile dysfunction.
In the medical literature the less precise term, "impotence" has been replaced by the term "erectile dysfunction." This term has been defined by the National Institutes of Health as the inability of the male to attain and maintain erection of the penis sufficient to penmit satisfactory sexual intercourse. J. Am. Med. Assoc., 270(1):83-90 (1993).
Because adequate arterial blood supply is critical for erection, any disorder that impairs blood flow may be implicated in the etiology of erectile failure. Erectile dysfunction affects millions of men and, although generally regarded as a benign disorder, has a profound impact on their quality of life. It is recognized, however, that in many men psychological desire, orgasmic capacity, and ejaculatory capacity are intact even in the presence of erectile dysfunction.
Etiological factors for erectile disorders have been categorized as psychogenic or organic in origin. Organic factors include those of a neurogenic origin and those of a vasculogenic origin. Neurogenic factors include, for example, lesions of the somatic nervous pathways which may impair reflexogenic erections and interrupt tactile sensations needed to maintain erections, and spinal cord lesions which, depending upon their location and severity, may produce varying degrees of erectile failure.
Psychogenic factors for erectile dysfunction include such processes as depression, anxiety, and relationship problems which can impair erectile functioning by reducing erotic focus or otherwise reducing awareness of sensory experience. This may lead to an inability to initiate or maintain an erection.
Vasculogenic risk factors include factors which affect blood flow and include cigarette smoking, diabetes mellitus, hypertension, vascular disease, high levels of serum cholesterol, low levels of high-density lipoprotein (HDL), and other chronic disease conditions such as arthritis. The Massachusetts Male Aging Study (MMAS, as reported by H. A. Feldman, et al., J.J. Urol.,15I : 54-61 ( 1994) found, for example, that the age-adjusted probability of complete erectile dysfunction was three times greater in subjects reporting treated diabetes than in those without diabetes. While there is some disagreement as to which of the many aspects of diabetes is the direct cause of erectile dysfunction, vascular disease is most frequently cited.
The MMAS also found a significant correlation between erectile dysfunction and heart disease with two of its associated risk factors, hypertension and low serum high density lipoprotein (HDL). It has been reported that 8-10% of all untreated hypertensive patients are impotent at the time they are diagnosed with hypertension. The association of erectile dysfunction with vascular disease in the literature is strong, with impairments in the hemodynamics of erection demonstrated in patients with myocardial infarction, coronary bypass surgery, cerebrovascular accidents, and peripheral vascular disease. The MMAS also found cigarette smoking to be an independent risk factor for vasculogenic erectile dysfunction, with cigarette smoking found to exacerbate the risk of erectile dysfunction associated with cardiovascular diseases.
The treatment of erectile dysfunction varies, depending upon the root causes of the condition in a particular patient. The mode of treatment may involve the use psychotherapeutic, surgical, mechanical, or pharmacotherapeutic methodology.
Psychotherapy and/or behavioral therapy are often useful for some patients with erectile dysfunction with no obvious organic cause (psychogenic). Venous litigation is effective in the treatment of patients who have difficulty maintaining an erection due to demonstrated venous leakage from the corpus cavernosa. Vacuum constriction devices are sometimes effective in generating and maintaining erections in patients with erectile dysfunction, and semi-rigid, malleable, or inflatable penile prostheses are available for patients who fail or refuse other forms of therapy.
ORGANIC
ERECTILE DYSFUNCTION IN MALES
This invention relates to medical methods of treatment. More particularly, the invention concerns the use of apomorphine for the treatment of organic erectile dysfunction in males, particularly vasculogenic erectile dysfunction.
In the medical literature the less precise term, "impotence" has been replaced by the term "erectile dysfunction." This term has been defined by the National Institutes of Health as the inability of the male to attain and maintain erection of the penis sufficient to penmit satisfactory sexual intercourse. J. Am. Med. Assoc., 270(1):83-90 (1993).
Because adequate arterial blood supply is critical for erection, any disorder that impairs blood flow may be implicated in the etiology of erectile failure. Erectile dysfunction affects millions of men and, although generally regarded as a benign disorder, has a profound impact on their quality of life. It is recognized, however, that in many men psychological desire, orgasmic capacity, and ejaculatory capacity are intact even in the presence of erectile dysfunction.
Etiological factors for erectile disorders have been categorized as psychogenic or organic in origin. Organic factors include those of a neurogenic origin and those of a vasculogenic origin. Neurogenic factors include, for example, lesions of the somatic nervous pathways which may impair reflexogenic erections and interrupt tactile sensations needed to maintain erections, and spinal cord lesions which, depending upon their location and severity, may produce varying degrees of erectile failure.
Psychogenic factors for erectile dysfunction include such processes as depression, anxiety, and relationship problems which can impair erectile functioning by reducing erotic focus or otherwise reducing awareness of sensory experience. This may lead to an inability to initiate or maintain an erection.
Vasculogenic risk factors include factors which affect blood flow and include cigarette smoking, diabetes mellitus, hypertension, vascular disease, high levels of serum cholesterol, low levels of high-density lipoprotein (HDL), and other chronic disease conditions such as arthritis. The Massachusetts Male Aging Study (MMAS, as reported by H. A. Feldman, et al., J.J. Urol.,15I : 54-61 ( 1994) found, for example, that the age-adjusted probability of complete erectile dysfunction was three times greater in subjects reporting treated diabetes than in those without diabetes. While there is some disagreement as to which of the many aspects of diabetes is the direct cause of erectile dysfunction, vascular disease is most frequently cited.
The MMAS also found a significant correlation between erectile dysfunction and heart disease with two of its associated risk factors, hypertension and low serum high density lipoprotein (HDL). It has been reported that 8-10% of all untreated hypertensive patients are impotent at the time they are diagnosed with hypertension. The association of erectile dysfunction with vascular disease in the literature is strong, with impairments in the hemodynamics of erection demonstrated in patients with myocardial infarction, coronary bypass surgery, cerebrovascular accidents, and peripheral vascular disease. The MMAS also found cigarette smoking to be an independent risk factor for vasculogenic erectile dysfunction, with cigarette smoking found to exacerbate the risk of erectile dysfunction associated with cardiovascular diseases.
The treatment of erectile dysfunction varies, depending upon the root causes of the condition in a particular patient. The mode of treatment may involve the use psychotherapeutic, surgical, mechanical, or pharmacotherapeutic methodology.
Psychotherapy and/or behavioral therapy are often useful for some patients with erectile dysfunction with no obvious organic cause (psychogenic). Venous litigation is effective in the treatment of patients who have difficulty maintaining an erection due to demonstrated venous leakage from the corpus cavernosa. Vacuum constriction devices are sometimes effective in generating and maintaining erections in patients with erectile dysfunction, and semi-rigid, malleable, or inflatable penile prostheses are available for patients who fail or refuse other forms of therapy.
Pharmacolagic agents which have been used in the treatment of erectile dysfunction include vasodilators which are injected directly into the body of the penis, as well as orally administered agents. The most effective and well-studied of the injectable vasodilators are papaverine hydrochloride, phentolamine, and alprostadil, used singly or in combination. However, use of penile vasodilators can be problematic in patients who cannot tolerate transient hypotension. Orally administered agents include yohimbine, bromocriptine, fluoxetine, trazadone, trental, sildenafil, phentolamine, and extracts of ginkgoacea biloba.
United States Patent 5,770,606 discloses the sub-lingual administration of apomorphine for the treatment of psychogenic erectile dysfunction in males.
Apomorphine, a derivative of morphine, was first evaluated for use as a pharmacologic agent as an emetic in 1869. In the first half of the 20't' century, apomorphine was used as a sedative for psychiatric disturbances and as a behavior-altering agent for alcoholics and addicts. By 1967, the dopaminergic effects of apomorphine were realized, and the compound underwent intensive evaluation for the treatment of Parkinsonism.
Since that time, apomorphine has been classified as a selective dopamine receptor agonist that stimulates the central nervous system producing an arousal response manifested by yawning and penile erection in animals and man.
It has been found, in accordance with the present invention that organic erectile dysfunction in a male can be effectively treated or ameliorated by administering to a male in need of such treatment a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof. In particular, organic erectile dysfunction having a vasculogenic origin is effectively treated by oral administration of apomorphine.
In accordance with the invention, apomorphine is administered in an amount sufficient to produce an effective penile erection, but insufficient to induce nausea, typically in doses which result in an amount sufficient to establish plasma concentration levels of apomorphine preferably ranging up to about 5.5 nanograms/mL. The compound or one of its appropriate salts or pro-drugs may be administered alone or, if needed at the higher end of the dose range, in combination with an anti-emetic agent.
As used throughout this specification and the appended claims, the term "vasculogenic erectile dysfunction" refers to the condition whereby a male is incapable of initiating andlor maintaining a penile erection sufficient for satisfactory intercourse due to diminished blood flow accompanying a disease of the cardiovascular system and/or an associated risk factor. Such diseases include, but are not limited to, myocardial infarction, heart disease, peripheral vascular disease, and impaired circulation resulting from diabetes, cigarette smoking, cardiac bypass surgery, and cerebrovascular accidents.
Associated risk factors include hypertension, elevated serum low-density lipoprotein (LDL) and low serum high density lipoprotein (HDL).
The terms "acute dose" or ""acute administration" mean the scheduled administration of a drug to the patient on an as-needed basis.
The term "co-administration" of two or more pharmacologic agents means the administration of the two or more agents together in a single unit dosage form or, alternatively, in two or more separate unit dosage forms, one immediately following the other.
The terms "effective vasocongestive arousal" or "effective erection" mean, the swelling or tumescence of the male penis sufficient to effect vaginal penetration.
The method of treatment of the present invention involves the administration of apomorphine or one of its pharmaceutically acceptable acid addition salts, pro-drug or pro-drug ester to a patient suffering vasculogenic erectile dysfiuiction.
Apomorphine, (R)-5,6,6a,7-tetrahydro-6-methyl-(41~- dibenzo[de,g]quinoline-10,11-diol, is a derivative of morphine obtained by treatment of the latter with concentrated hydrochloric acid (L. Small, et al., J. Org~Chem., 5: 334 (1940)) or by heating morphine with zinc chloride (Mayer, ~, 4: 171 ( 1871 )). The compound has the chemical structure:
Apomorphine and possesses a cairal center at position 6a. The total synthesis of the racemic mixture is reported by J. L. Neumeyer, et al., J. Pharm. Sci., 59:1850 (1970) and the synthesis of the separate enantiomers by V. J. Ram and J. L. Neumeyer, J. Org. Ghem., 46:
(1981). The compound possesses a basic nitrogen atom at position 6 and is thus capable of existing in the free base form as well as acid addition salt forms.
The compound may be administered as the free base or in the form of one of its more soluble pharmaceutically acceptable salts or pro-drug derivatives.
Administration of the racermic form, or either of the enantionmers, alone, or in various combinations, is contemplated as falling within the scope of this invention.
As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts are well known in the art. For example, S.
M. Berge, et al. describe pharmaceutically acceptable salts in detail in J.
Pharmaceutical Sciences, 66: 1-19 (1977). The salts are prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, malefic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
The term "pro-drug" refers to compounds that are rapidly transformed in vivo to yield the parent compound, as for example, by hydrolysis in blood. T. Higuchi and V.
Stella provide a thorough discussion of the pro-drug concept in "Pro-drugs as Novel Delivery Systems", Vol. 14 of the A.C.S. Symposium Series, American Chemical Society (1975). Examples of esters useful as pro-drugs for compounds containing carboxyl groups may be found on pages 14-21 of "Bioreversible Garners in Drug Design:
Theory and Application," edited by E.B. Roche, Pergamon Press (1987).
The term "pro-drug ester group" refers to any of several ester-forming groups that are hydrolyzed under physiological conditions. Examples of pro-drug ester groups include pivoyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art.
As used herein, the term "pharmaceutically acceptable ester" of apomorphine refers to esters formed with one or both of the hydroxyl functions at positions 10 and 11, and which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters includes formates, acetates, propionates, butryates, acrylates and ethylsuccinates.
For an optimal vasocongestive arousal response (erection) in the male, steady state circulating serum and mid-brain tissue levels of apomorphine should be maintained within a relatively closely defined range. The drug is preferably administered in a formulation which rapidly delivers the drug to the system while maintaining and not exceeding the desired systemic levels of the drug. Methods known to the practitioner of the pharmaceutical formulation arts which accomplishes this means may be used.
For example, the drug may be delivered to the system by means of a solid oral formulation, by a liquid formulation, including one applied as drops sub-lingually; by a tablet, lozenge, or lollipop held in the mouth and absorbed buccally or sublingually;
by means of a suppository formulation administered rectally; or by a powder, gel, or suspension, or an infra-nasal spray formulation. The drug may also be administered in a sterile parenteral formulation by sub-cutaneous or intramuscular route, although sub-lingual, buccal, infra-nasal, and suppository formulations are preferred because of their greater ease of administration and the resulting greater potential for patient acceptance.
Sublingual apomorphine dosage forms, usually containing about 2.5 to about 10 milligrams of apomorphine, are useful in treating the symptoms of male vasculogenic sexual dysfunction, including its symptomatic manifestations without nausea or other undesirable side effects. The apomorphine is administered in the time period immediately prior to sexual intercourse, generally during the period between about 2 minutes and 120 minutes prior to sexual relations, preferably during the period between about 2 minutes and about 60 minutes prior to sexual relations so as to maintain a predetermined circulating serum levels and mid-brain tissue levels of apomorphine during the period of sexual activity sufficient to induce and maintain penile erection adequate for intercourse (i.e. "effective vasocongestive arousal") but less than the amount that induces nausea. Plasma concentrations of apomorphine are preferably maintained at between about 0.3 to 5.5 nanograms per milliliter, preferably between about 0.3 to about 4 nanograms per milliliter, and more preferably between about 1 to about 2 nanograms per milliliter.
Apomorphine is a dopamine receptor agonist that has a recognized use as an emetic when administered subcutaneously in about a 5-milligram dose. For the purposes of the present invention, apomorphine is administered in an amount sufficient to excite cells in the mid-brain region of the patient but with minimal side effects. This cell excitation is believed to be part of a cascade of stimulation that is likely to include neurotransmission with serotonin and oxytocin.
The dopamine receptors in the mid-brain region of a patient can be stimulated to a degree sufficient to cause an erectile response without inducing nausea by the administration, preferably sublingually, of apomorphine so as to maintain a plasma concentration of apamorphine of no more than about 5.5 nanograms per milliliter (5.5 ng/mI). The sublingual administration usually takes place over a time period in the range of about 2 to about 10 minutes, or longer. The amount of apomorphine administered sublingually over this time period preferably is in the range of about 25 micrograms per kilogram (pg/kg).of body weight to about 60 p.g/kg of body weight.
In sensitive patients experiencing nausea, the onset of nausea can be obviated or delayed by delivering apomorphine at a controlled dissolution rate so as to provide circulating serum levels and midbrain tissue levels of apomorphine less than 5.5 nanograms/mL. When apomorphine is administered at or near the higher amounts of the aforementioned dosage range, the likelihood of the onset of nausea can be reduced by concurrent administration of a ganglionic agent (inhibitor of ganglionic response) such as nicotine or Iobeline sulfate. For this purpose, the weight ratio of apomorphine to ganglionic agent is in the range of about 10 to about 1.
Other antiemetic agents that can be used in conjunction with apomorphine are antidopaminergic agents such as metoclopramide, and the phenothiazines, e.g., chlorpromazine, prochlorperazine, pipamazine, thiethylperazine, oxypendyl _g_ hydrochloride, and the like. Also suitable are the serotonin (5-hydroxytryptamine or 5-HT) antagonists such as domperidone, ondansetron (commercially available as the hydrochloride salt under the designation ZofranTM), and the like, the histamine antagonists such as buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate (DramamineTM), and the like, the parasympathetic depressants such as scopolamine, and the like, as well as other anti-emetics such as metopimazine, trimethobenzamide, benzauinarnine hydrochloride, diphenidol hydrochloride, and the like.
Illustrative preferred sublingual dosage forms are set forth in Table I, below.
Table I
150-Milligram Apomorphine Hydrochloride Sublingual Tablets Apomorphme Hydrochloride 2.00 wt-Mannitol 66.67 wt-Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-Avicel PH 102 15.00 Wt Methocel E4 10.00 Wt-Aspartame 0.67 wt-Magnesium stearate 0.33 wt-4-m g Tablet Apomorphine Hydrochloride 2.66 wt Mannitol 66.00 wt-Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-WO 00/35457 PCT/US99l29449 Avicel PH 102 15.00 wt Methocel E4M 10 00 wt-.
Aspartame 0.67 wt-Magnesium stearate ~ 0.33 wt-Apomorphme Hydrochloride 3.33 wt Mannitol 65.34 wt-Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-Avicel PH102 15.00 wt Methocel E4M 10.00 wt-e 0.67 wt-Magnesium stearate 0.33 wt-If desired, and in order to facilitate absorption and thus bioavailability, the presently contemplated dosage forms can also contain, in addition to tabletting excipients, ~3-cyclodextrin or a ~i-cyclodextrin derivative such as hydroxypropyl-(3-cyclodextrin (HPBCD). Illustrative dosage forms containing HPBCD are shown in Tables II and III, below.
Table II
Apomorphine Hydrochloride Sublingual Tablets With Hydroxypropyl-(3-Cyclodextrin ed~ent mg/Tab Apomorphine hydrochloride 4.0 HPBCD 5.0 Ascorbic acid 10.0 -lo-PEG 8000 39.5 MannitoI 39.5 Aspartame 2.0 Total ~ 100.0 Table III
Apomorphine Hydrochloride Sublingual Tablets With ~3-Cyclodextrin Apomorphine hydrochloride 5.0 (3-Cyclodextrin 20.0 Ascorbic acid 5.0 Mannitol 68.9 Magnesium stearate 1.0 D&C Yellow 10 aluminum lake 0.1 ivl~ 100.0 Nicotine- and domperidone-containing dosage forms are illustrated in Table IV, below.
Table IV
Apomorphine Hydrochloride Sublingual Tablets Containing an Anti-Emetic Agent Nicotine-containing atat blet Apomorphine Hydrochloride 5.0 Ascorbic Acid 5.0 Mannitol 67.9 Magnesium Stearate 1.0 Nicotine 1.0 (3-Cyclodextrin 20.0 D&C Yellow aluminum lake 0.1 TOTAL 100.0 Apomorphine Hydrochloride S.0 Ascorbic Acid 5.0 Mannitol Sg.9 Magnesium Stearate 1.0 Domperidone 10.0 ~i-Cyclodextrin 20.0 D&C Yellow 10 aluminum lake 0.1 1 ~ 1 Eu., 100.0 The preferred sublingual dosage forms dissolve within a time period of less than about 10 minutes. The dissolution time can be essentially instantaneous or, if desired, as long as the necessary plasma concentration of apomorphine is to be maintained.
Preferably, the dissolution time in water for the presently contemplated dosage forms is about 3 minutes to about S minutes.
A mufti-center, double-blind, randomized, placebo-controlled, three-armed study was conducted on patients diagnosed with male erectile dysfunction. For each sequence, patients received placebo in one of the treatment periods, and a dose (2 mg, 4 mg, 5 mg, or 6 mg) of apomorphine in the other treatment period. This arrangement resulted in approximately one-third of the patients receiving one of the three apomorphine doses.
During treatment periods of the study, patients and their sexual partners were instructed to attempt intercourse a minimum of twice weekly. Each time the study drug was taken, a questionnaire was completed by the patient and mailed to the study sponsor.
The questionnaire recorded the date and time the study drug was taken, an evaluation of the erection, whether or not sexual intercourse had occurred, and satisfaction associated with each attempt. The patient also completed a diary which recorded the latency and duration of erections associated with the use of the study drug and anti-emetic and concomitant medication usage and any adverse effects. If an erection occurred after administration to the patient of the study drug, the duration of erection and time-to-erection were recorded in the patient diary. The data from these studies were analyzed, and the results from patients who were diagnosed as hypertensive, or who were taking a hypertensive medication, were tabulated. These study results appear in Tables V-VII
below.
Table V shows the responses on the questionnaire question, "Did you achieve an erection firm enough for intercourse?" of study participants receiving placebo or one of four doses (2 mg, 4, mg, 5 mg, or 6 mg) of apomorphine.
Table V
Erection Firm Enough for Intercourse (Based on Attempts*) Dose Noof Resno~g A t m ~P r . n 1 Attempts--- er .n ) p_Value ~tients 2 mg 65 Yes 210 43.30 162 34.11 0.028 2 mg No 275 56.70 309 65.61 4 mg 53 Yes 202 52.60 105 27.06 <0.001 4 mg No 182 47.40 283 72.94 S mg 26 Yes 95 49.48 62 30.85 0.022 mg No 97 50.52 139 69.1 S
6 mg 50 Yes 233 62.13 119 32.96 <0.001 6 mg No 142 37.87 242 67.04 * An "attempt" was defined as the taking of study drug and completion of the appropriate questionnaire efficacy question.
The data in Table V show that apomorphine, at each dose tested, significantly increased the percentage of reported erections which were firm enough for intercourse.
While not holding to one theory to the exclusion of others, it is believed that the slightly lower "yes" responses for the 5 mg dose when compared with the 4 mg dose reflects the smaller patient population for the S mg dose study.
Table VI shows the "success" responses on the questionnaire from study participants receiving placebo or one of four doses (2 mg, 4, mg, 5 mg, or 6 mg) of apomorphine. A treatment was deemed a "success" for a patient if at least 50%
of the first eight attempts while using the treatment resulted in erections firm enough for intercourse. Table VI shows the percentages of patients classified as treatment success.
The results show success rates of 68.0% for drug vs. 38.8% for placebo at the 6 mg drug dose; 53.8% for drug vs. 38.5% for placebo at the 5 mg drug dose; 62.3% for drug vs.
Table VI
"Successful" Erections Firm Enough for Intercourse Placebo SuccessfulNot SuccessfulTotal Successful 21 (32.3%)8 (12.3%) 29 (44.6%) Apomorphine Not Successful4 (6.2%) 32 (49.2%) 36 (55.4%) 2 mg Total 25 (38.5%)40 (61.5%) 65 (100%) Placebo SuccessfulNot SuccessfulTotal r successful 12 (22.6%) 21 (39.6%) 33 (62.3%) Apomorphine 4 mg Not Successful 3 (5.7%) 17 (32.1 %) 20 (37.7%) Total 15 (28.3%) 38 (71.7%) 53 (100%) Placebo Successful Not Successful Total Successful 8 (30.8%) 6 (23.1 %) 14 (53.8%) Apomorphine s mg Not Successful 2 (7.7%) 10 (38.5%) 12 (46.2%) Total 10 (38.5%) 16 (61.5%) 26 (100%) Placebo Successful Not Successful Total Successful 18 (36.0%) 16 (32.0%) 34 (68.0%) Apomorphine 6 mg Not Successful 1 (2.0%) 15 (30.0%) 16 (32.0%) Total- I 19 (38.0%) I 31 (62.0%) I s0 (100%) 26.9% for placebo at the 4 mg drug dose; and 44.6% for drug vs. 38.s% for placebo at the 2 mg drug dose. The results were statistically significant for the 4 mg and 6 mg doses; while showing a favorable success rate for the 2 mg and 5 mg doses, the lack of statistical significance is possibly due to the small sample size.
Finally, Table VII shows the results of the number of attempts which actually resulted in intercourse as reported by study participants on the questionnaire.
Table VII
Attempt Resulted in Intercourse (Based on First Eight Attempts*) -1s-~~Ip~llll~ Place.~g Dose No-of $~,s onse Attem t~s ~P~ Attem tt P r n 1 Patients P-Value 2 mg 6S Yes 18S 38.22 148 31.36 0 2 mg No 299 61.78 324 68.64 .
4 mg S2 Yes 183 47.66 87 22.96 <0 4 mg No 201 52.34 292 77.04 .
mg 26 Yes 100 52.08 62 30.85 0.012 S mg No 92 47.92 140 69.65 6 mg SO Yes 20S 56.01 96 26.67 <0.001 6 mg No 161 43.99 264 73.33 "' An "attempt"
was defined as the taking of study drug and completion of the a ro i t pp uestionnaire efficacy question. pr a e q The results presented in Table VII parallel those of Table V, with the percentage of attempts which resulted in intercourse being 56.01% for drug vs. 26.67% for placebo at the 6 mg drug dose; 52.08% for drug vs. 30.35% for placebo at the S mg drug dose;
47.66% for drug vs. 22.96% for placebo at the 4 mg drug dose; and 38.22% for drug vs.
31.36% for placebo at the 2 mg drug dose.
The data presented in Tables V-VII demonstrate that the administration of apomorphine to males suffering hypertension, a representative vasculogenic cause for erectile dysfunction, is successful in treating or ameliorating the condition.
While there have been shown and described what are believed to be the preferred embodiments of the present invention, it will be clear to one of ordinary skill in the art that various modifications can be made in the practice of the invention without departing from its scope as defined by the appended claims.
United States Patent 5,770,606 discloses the sub-lingual administration of apomorphine for the treatment of psychogenic erectile dysfunction in males.
Apomorphine, a derivative of morphine, was first evaluated for use as a pharmacologic agent as an emetic in 1869. In the first half of the 20't' century, apomorphine was used as a sedative for psychiatric disturbances and as a behavior-altering agent for alcoholics and addicts. By 1967, the dopaminergic effects of apomorphine were realized, and the compound underwent intensive evaluation for the treatment of Parkinsonism.
Since that time, apomorphine has been classified as a selective dopamine receptor agonist that stimulates the central nervous system producing an arousal response manifested by yawning and penile erection in animals and man.
It has been found, in accordance with the present invention that organic erectile dysfunction in a male can be effectively treated or ameliorated by administering to a male in need of such treatment a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof. In particular, organic erectile dysfunction having a vasculogenic origin is effectively treated by oral administration of apomorphine.
In accordance with the invention, apomorphine is administered in an amount sufficient to produce an effective penile erection, but insufficient to induce nausea, typically in doses which result in an amount sufficient to establish plasma concentration levels of apomorphine preferably ranging up to about 5.5 nanograms/mL. The compound or one of its appropriate salts or pro-drugs may be administered alone or, if needed at the higher end of the dose range, in combination with an anti-emetic agent.
As used throughout this specification and the appended claims, the term "vasculogenic erectile dysfunction" refers to the condition whereby a male is incapable of initiating andlor maintaining a penile erection sufficient for satisfactory intercourse due to diminished blood flow accompanying a disease of the cardiovascular system and/or an associated risk factor. Such diseases include, but are not limited to, myocardial infarction, heart disease, peripheral vascular disease, and impaired circulation resulting from diabetes, cigarette smoking, cardiac bypass surgery, and cerebrovascular accidents.
Associated risk factors include hypertension, elevated serum low-density lipoprotein (LDL) and low serum high density lipoprotein (HDL).
The terms "acute dose" or ""acute administration" mean the scheduled administration of a drug to the patient on an as-needed basis.
The term "co-administration" of two or more pharmacologic agents means the administration of the two or more agents together in a single unit dosage form or, alternatively, in two or more separate unit dosage forms, one immediately following the other.
The terms "effective vasocongestive arousal" or "effective erection" mean, the swelling or tumescence of the male penis sufficient to effect vaginal penetration.
The method of treatment of the present invention involves the administration of apomorphine or one of its pharmaceutically acceptable acid addition salts, pro-drug or pro-drug ester to a patient suffering vasculogenic erectile dysfiuiction.
Apomorphine, (R)-5,6,6a,7-tetrahydro-6-methyl-(41~- dibenzo[de,g]quinoline-10,11-diol, is a derivative of morphine obtained by treatment of the latter with concentrated hydrochloric acid (L. Small, et al., J. Org~Chem., 5: 334 (1940)) or by heating morphine with zinc chloride (Mayer, ~, 4: 171 ( 1871 )). The compound has the chemical structure:
Apomorphine and possesses a cairal center at position 6a. The total synthesis of the racemic mixture is reported by J. L. Neumeyer, et al., J. Pharm. Sci., 59:1850 (1970) and the synthesis of the separate enantiomers by V. J. Ram and J. L. Neumeyer, J. Org. Ghem., 46:
(1981). The compound possesses a basic nitrogen atom at position 6 and is thus capable of existing in the free base form as well as acid addition salt forms.
The compound may be administered as the free base or in the form of one of its more soluble pharmaceutically acceptable salts or pro-drug derivatives.
Administration of the racermic form, or either of the enantionmers, alone, or in various combinations, is contemplated as falling within the scope of this invention.
As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
Pharmaceutically acceptable salts are well known in the art. For example, S.
M. Berge, et al. describe pharmaceutically acceptable salts in detail in J.
Pharmaceutical Sciences, 66: 1-19 (1977). The salts are prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, malefic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like.
The term "pro-drug" refers to compounds that are rapidly transformed in vivo to yield the parent compound, as for example, by hydrolysis in blood. T. Higuchi and V.
Stella provide a thorough discussion of the pro-drug concept in "Pro-drugs as Novel Delivery Systems", Vol. 14 of the A.C.S. Symposium Series, American Chemical Society (1975). Examples of esters useful as pro-drugs for compounds containing carboxyl groups may be found on pages 14-21 of "Bioreversible Garners in Drug Design:
Theory and Application," edited by E.B. Roche, Pergamon Press (1987).
The term "pro-drug ester group" refers to any of several ester-forming groups that are hydrolyzed under physiological conditions. Examples of pro-drug ester groups include pivoyloxymethyl, acetoxymethyl, phthalidyl, indanyl and methoxymethyl, as well as other such groups known in the art.
As used herein, the term "pharmaceutically acceptable ester" of apomorphine refers to esters formed with one or both of the hydroxyl functions at positions 10 and 11, and which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters includes formates, acetates, propionates, butryates, acrylates and ethylsuccinates.
For an optimal vasocongestive arousal response (erection) in the male, steady state circulating serum and mid-brain tissue levels of apomorphine should be maintained within a relatively closely defined range. The drug is preferably administered in a formulation which rapidly delivers the drug to the system while maintaining and not exceeding the desired systemic levels of the drug. Methods known to the practitioner of the pharmaceutical formulation arts which accomplishes this means may be used.
For example, the drug may be delivered to the system by means of a solid oral formulation, by a liquid formulation, including one applied as drops sub-lingually; by a tablet, lozenge, or lollipop held in the mouth and absorbed buccally or sublingually;
by means of a suppository formulation administered rectally; or by a powder, gel, or suspension, or an infra-nasal spray formulation. The drug may also be administered in a sterile parenteral formulation by sub-cutaneous or intramuscular route, although sub-lingual, buccal, infra-nasal, and suppository formulations are preferred because of their greater ease of administration and the resulting greater potential for patient acceptance.
Sublingual apomorphine dosage forms, usually containing about 2.5 to about 10 milligrams of apomorphine, are useful in treating the symptoms of male vasculogenic sexual dysfunction, including its symptomatic manifestations without nausea or other undesirable side effects. The apomorphine is administered in the time period immediately prior to sexual intercourse, generally during the period between about 2 minutes and 120 minutes prior to sexual relations, preferably during the period between about 2 minutes and about 60 minutes prior to sexual relations so as to maintain a predetermined circulating serum levels and mid-brain tissue levels of apomorphine during the period of sexual activity sufficient to induce and maintain penile erection adequate for intercourse (i.e. "effective vasocongestive arousal") but less than the amount that induces nausea. Plasma concentrations of apomorphine are preferably maintained at between about 0.3 to 5.5 nanograms per milliliter, preferably between about 0.3 to about 4 nanograms per milliliter, and more preferably between about 1 to about 2 nanograms per milliliter.
Apomorphine is a dopamine receptor agonist that has a recognized use as an emetic when administered subcutaneously in about a 5-milligram dose. For the purposes of the present invention, apomorphine is administered in an amount sufficient to excite cells in the mid-brain region of the patient but with minimal side effects. This cell excitation is believed to be part of a cascade of stimulation that is likely to include neurotransmission with serotonin and oxytocin.
The dopamine receptors in the mid-brain region of a patient can be stimulated to a degree sufficient to cause an erectile response without inducing nausea by the administration, preferably sublingually, of apomorphine so as to maintain a plasma concentration of apamorphine of no more than about 5.5 nanograms per milliliter (5.5 ng/mI). The sublingual administration usually takes place over a time period in the range of about 2 to about 10 minutes, or longer. The amount of apomorphine administered sublingually over this time period preferably is in the range of about 25 micrograms per kilogram (pg/kg).of body weight to about 60 p.g/kg of body weight.
In sensitive patients experiencing nausea, the onset of nausea can be obviated or delayed by delivering apomorphine at a controlled dissolution rate so as to provide circulating serum levels and midbrain tissue levels of apomorphine less than 5.5 nanograms/mL. When apomorphine is administered at or near the higher amounts of the aforementioned dosage range, the likelihood of the onset of nausea can be reduced by concurrent administration of a ganglionic agent (inhibitor of ganglionic response) such as nicotine or Iobeline sulfate. For this purpose, the weight ratio of apomorphine to ganglionic agent is in the range of about 10 to about 1.
Other antiemetic agents that can be used in conjunction with apomorphine are antidopaminergic agents such as metoclopramide, and the phenothiazines, e.g., chlorpromazine, prochlorperazine, pipamazine, thiethylperazine, oxypendyl _g_ hydrochloride, and the like. Also suitable are the serotonin (5-hydroxytryptamine or 5-HT) antagonists such as domperidone, ondansetron (commercially available as the hydrochloride salt under the designation ZofranTM), and the like, the histamine antagonists such as buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate (DramamineTM), and the like, the parasympathetic depressants such as scopolamine, and the like, as well as other anti-emetics such as metopimazine, trimethobenzamide, benzauinarnine hydrochloride, diphenidol hydrochloride, and the like.
Illustrative preferred sublingual dosage forms are set forth in Table I, below.
Table I
150-Milligram Apomorphine Hydrochloride Sublingual Tablets Apomorphme Hydrochloride 2.00 wt-Mannitol 66.67 wt-Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-Avicel PH 102 15.00 Wt Methocel E4 10.00 Wt-Aspartame 0.67 wt-Magnesium stearate 0.33 wt-4-m g Tablet Apomorphine Hydrochloride 2.66 wt Mannitol 66.00 wt-Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-WO 00/35457 PCT/US99l29449 Avicel PH 102 15.00 wt Methocel E4M 10 00 wt-.
Aspartame 0.67 wt-Magnesium stearate ~ 0.33 wt-Apomorphme Hydrochloride 3.33 wt Mannitol 65.34 wt-Ascorbic Acid 3.33 wt-Citric Acid 2.00 wt-Avicel PH102 15.00 wt Methocel E4M 10.00 wt-e 0.67 wt-Magnesium stearate 0.33 wt-If desired, and in order to facilitate absorption and thus bioavailability, the presently contemplated dosage forms can also contain, in addition to tabletting excipients, ~3-cyclodextrin or a ~i-cyclodextrin derivative such as hydroxypropyl-(3-cyclodextrin (HPBCD). Illustrative dosage forms containing HPBCD are shown in Tables II and III, below.
Table II
Apomorphine Hydrochloride Sublingual Tablets With Hydroxypropyl-(3-Cyclodextrin ed~ent mg/Tab Apomorphine hydrochloride 4.0 HPBCD 5.0 Ascorbic acid 10.0 -lo-PEG 8000 39.5 MannitoI 39.5 Aspartame 2.0 Total ~ 100.0 Table III
Apomorphine Hydrochloride Sublingual Tablets With ~3-Cyclodextrin Apomorphine hydrochloride 5.0 (3-Cyclodextrin 20.0 Ascorbic acid 5.0 Mannitol 68.9 Magnesium stearate 1.0 D&C Yellow 10 aluminum lake 0.1 ivl~ 100.0 Nicotine- and domperidone-containing dosage forms are illustrated in Table IV, below.
Table IV
Apomorphine Hydrochloride Sublingual Tablets Containing an Anti-Emetic Agent Nicotine-containing atat blet Apomorphine Hydrochloride 5.0 Ascorbic Acid 5.0 Mannitol 67.9 Magnesium Stearate 1.0 Nicotine 1.0 (3-Cyclodextrin 20.0 D&C Yellow aluminum lake 0.1 TOTAL 100.0 Apomorphine Hydrochloride S.0 Ascorbic Acid 5.0 Mannitol Sg.9 Magnesium Stearate 1.0 Domperidone 10.0 ~i-Cyclodextrin 20.0 D&C Yellow 10 aluminum lake 0.1 1 ~ 1 Eu., 100.0 The preferred sublingual dosage forms dissolve within a time period of less than about 10 minutes. The dissolution time can be essentially instantaneous or, if desired, as long as the necessary plasma concentration of apomorphine is to be maintained.
Preferably, the dissolution time in water for the presently contemplated dosage forms is about 3 minutes to about S minutes.
A mufti-center, double-blind, randomized, placebo-controlled, three-armed study was conducted on patients diagnosed with male erectile dysfunction. For each sequence, patients received placebo in one of the treatment periods, and a dose (2 mg, 4 mg, 5 mg, or 6 mg) of apomorphine in the other treatment period. This arrangement resulted in approximately one-third of the patients receiving one of the three apomorphine doses.
During treatment periods of the study, patients and their sexual partners were instructed to attempt intercourse a minimum of twice weekly. Each time the study drug was taken, a questionnaire was completed by the patient and mailed to the study sponsor.
The questionnaire recorded the date and time the study drug was taken, an evaluation of the erection, whether or not sexual intercourse had occurred, and satisfaction associated with each attempt. The patient also completed a diary which recorded the latency and duration of erections associated with the use of the study drug and anti-emetic and concomitant medication usage and any adverse effects. If an erection occurred after administration to the patient of the study drug, the duration of erection and time-to-erection were recorded in the patient diary. The data from these studies were analyzed, and the results from patients who were diagnosed as hypertensive, or who were taking a hypertensive medication, were tabulated. These study results appear in Tables V-VII
below.
Table V shows the responses on the questionnaire question, "Did you achieve an erection firm enough for intercourse?" of study participants receiving placebo or one of four doses (2 mg, 4, mg, 5 mg, or 6 mg) of apomorphine.
Table V
Erection Firm Enough for Intercourse (Based on Attempts*) Dose Noof Resno~g A t m ~P r . n 1 Attempts--- er .n ) p_Value ~tients 2 mg 65 Yes 210 43.30 162 34.11 0.028 2 mg No 275 56.70 309 65.61 4 mg 53 Yes 202 52.60 105 27.06 <0.001 4 mg No 182 47.40 283 72.94 S mg 26 Yes 95 49.48 62 30.85 0.022 mg No 97 50.52 139 69.1 S
6 mg 50 Yes 233 62.13 119 32.96 <0.001 6 mg No 142 37.87 242 67.04 * An "attempt" was defined as the taking of study drug and completion of the appropriate questionnaire efficacy question.
The data in Table V show that apomorphine, at each dose tested, significantly increased the percentage of reported erections which were firm enough for intercourse.
While not holding to one theory to the exclusion of others, it is believed that the slightly lower "yes" responses for the 5 mg dose when compared with the 4 mg dose reflects the smaller patient population for the S mg dose study.
Table VI shows the "success" responses on the questionnaire from study participants receiving placebo or one of four doses (2 mg, 4, mg, 5 mg, or 6 mg) of apomorphine. A treatment was deemed a "success" for a patient if at least 50%
of the first eight attempts while using the treatment resulted in erections firm enough for intercourse. Table VI shows the percentages of patients classified as treatment success.
The results show success rates of 68.0% for drug vs. 38.8% for placebo at the 6 mg drug dose; 53.8% for drug vs. 38.5% for placebo at the 5 mg drug dose; 62.3% for drug vs.
Table VI
"Successful" Erections Firm Enough for Intercourse Placebo SuccessfulNot SuccessfulTotal Successful 21 (32.3%)8 (12.3%) 29 (44.6%) Apomorphine Not Successful4 (6.2%) 32 (49.2%) 36 (55.4%) 2 mg Total 25 (38.5%)40 (61.5%) 65 (100%) Placebo SuccessfulNot SuccessfulTotal r successful 12 (22.6%) 21 (39.6%) 33 (62.3%) Apomorphine 4 mg Not Successful 3 (5.7%) 17 (32.1 %) 20 (37.7%) Total 15 (28.3%) 38 (71.7%) 53 (100%) Placebo Successful Not Successful Total Successful 8 (30.8%) 6 (23.1 %) 14 (53.8%) Apomorphine s mg Not Successful 2 (7.7%) 10 (38.5%) 12 (46.2%) Total 10 (38.5%) 16 (61.5%) 26 (100%) Placebo Successful Not Successful Total Successful 18 (36.0%) 16 (32.0%) 34 (68.0%) Apomorphine 6 mg Not Successful 1 (2.0%) 15 (30.0%) 16 (32.0%) Total- I 19 (38.0%) I 31 (62.0%) I s0 (100%) 26.9% for placebo at the 4 mg drug dose; and 44.6% for drug vs. 38.s% for placebo at the 2 mg drug dose. The results were statistically significant for the 4 mg and 6 mg doses; while showing a favorable success rate for the 2 mg and 5 mg doses, the lack of statistical significance is possibly due to the small sample size.
Finally, Table VII shows the results of the number of attempts which actually resulted in intercourse as reported by study participants on the questionnaire.
Table VII
Attempt Resulted in Intercourse (Based on First Eight Attempts*) -1s-~~Ip~llll~ Place.~g Dose No-of $~,s onse Attem t~s ~P~ Attem tt P r n 1 Patients P-Value 2 mg 6S Yes 18S 38.22 148 31.36 0 2 mg No 299 61.78 324 68.64 .
4 mg S2 Yes 183 47.66 87 22.96 <0 4 mg No 201 52.34 292 77.04 .
mg 26 Yes 100 52.08 62 30.85 0.012 S mg No 92 47.92 140 69.65 6 mg SO Yes 20S 56.01 96 26.67 <0.001 6 mg No 161 43.99 264 73.33 "' An "attempt"
was defined as the taking of study drug and completion of the a ro i t pp uestionnaire efficacy question. pr a e q The results presented in Table VII parallel those of Table V, with the percentage of attempts which resulted in intercourse being 56.01% for drug vs. 26.67% for placebo at the 6 mg drug dose; 52.08% for drug vs. 30.35% for placebo at the S mg drug dose;
47.66% for drug vs. 22.96% for placebo at the 4 mg drug dose; and 38.22% for drug vs.
31.36% for placebo at the 2 mg drug dose.
The data presented in Tables V-VII demonstrate that the administration of apomorphine to males suffering hypertension, a representative vasculogenic cause for erectile dysfunction, is successful in treating or ameliorating the condition.
While there have been shown and described what are believed to be the preferred embodiments of the present invention, it will be clear to one of ordinary skill in the art that various modifications can be made in the practice of the invention without departing from its scope as defined by the appended claims.
Claims (20)
1. A method of treating organic erectile dysfunction in a male comprising administering to a male in need of such treatment a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
2. The method of Claim 1 wherein said organic erectile dysfunction is vasculogenic in origin relating to a disease of the cardiovascular system.
3. The method of Claim 1 wherein said organic erectile dysfunction is vasculogenic in origin relating to a risk factor associated with a disease of the cardiovascular system.
4. The method of Claim 2 wherein said disease of the cardiovascular system is myocardial infarction, heart disease, or peripheral vascular disease.
5. The method of Claim 2 wherein said disease of the cardiovascular system is impaired circulation associated with diabetes, cardiac bypass surgery, cerebral vascular trauma, or cigarette smoking.
6. The method of Claim 3 wherein said risk factor associated with a disease of the cardiovascular system is hypertension, elevated serum low-density lipoprotein (LDL) and low serum high-density lipoprotein (HDL).
7. The method of Claim 1 wherein said apomorphine is administered in an amount sufficient to produce an effective penile erection in said male, but insufficient to induce nausea.
8. The method of Claim 1 wherein said apomorphine is co-administered with an emesis inhibitory effective amount of an anti-emetic agent.
9. The method of Claim 1 wherein said apomorphine is administered in an amount between about 25 micrograms/kg of body weight and about 60 micrograms/kg of body weight.
10. The method of Claim 1 wherein said apomorphine is administered in an amount sufficient to establish plasma concentration levels of apomorphine ranging between about 0.3 to about 5.5 nanograms/mL.
11. The method of Claim 10 wherein said plasma levels of apomorphine range between about 0.3 and about 4 nanograms/mL.
12. The method of Claim 11 wherein said plasma levels of apomorphine range between about l and about 2 nanograms/mL.
13. The method of Claim 8 wherein said anti-emetic agent is selected from the group consisting of nicotine, lobeline sulfate, metoclopramide, chlorpromazine, prochlorperazine, pipamazine, thiethylperazine, oxypendyl hydrochloride, domperidone, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate,scopolamine, metopimazine, trimethobenzamide, benzauinamine hydrochloride, and diphenidol hydrochloride.
14. A method of treating erectile dysfunction in a hypertensive male comprising administering to a male in need of such treatment a therapeutically effective amount of apomorphine or a pharmaceutically acceptable salt, ester, or pro-drug thereof.
15. The method of Claim 14 wherein said apomorphine is co-administered with an emesis inhibitory effective amount of an anti-emetic agent.
16. The method of Claim 14 wherein said apomorphine is administered in an amount between about 25 micrograms/kg of body weight and about 60 micrograms/kg of body weight.
17. The method of Claim 14 wherein said apomorphine is administered in an amount sufficient to establish plasma concentration levels of apomorphine ranging between about 0.3 to about 5.5 nanograms/mL.
18. The method of Claim 17 wherein said plasma levels of apomorphine range between about 0.3 and about 4 nanograms/mL.
19. The method of Claim 18 wherein said plasma levels of apomorphine range between about l and about 2 nanograms/mL.
20. The method of Claim 15 wherein said anti-emetic agent is selected from the group consisting of nicotine, lobeline sulfate, metoclopramide, chlorpromazine, prochlorperazine, pipamazine, thiethylperazine, oxypendyl hydrochloride, domperidone, ondansetron, buclizine hydrochloride, cyclizine hydrochloride, dimenhydrinate,scopolamine, metopimazine, trimethobenzamide, benzauinamine hydrochloride, and diphenidol hydrochloride.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/213,567 | 1998-12-17 | ||
| US09/213,567 US6291471B1 (en) | 1998-12-17 | 1998-12-17 | Use of apomorphine for the treatment of organic erectile dysfunction in males |
| PCT/US1999/029449 WO2000035457A1 (en) | 1998-12-17 | 1999-12-13 | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2354601A1 true CA2354601A1 (en) | 2000-06-22 |
Family
ID=22795606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002354601A Abandoned CA2354601A1 (en) | 1998-12-17 | 1999-12-13 | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6291471B1 (en) |
| EP (1) | EP1140094A1 (en) |
| JP (1) | JP2003521462A (en) |
| KR (1) | KR20010101241A (en) |
| CN (1) | CN1335772A (en) |
| AR (1) | AR021912A1 (en) |
| AU (1) | AU2175800A (en) |
| BG (1) | BG105664A (en) |
| BR (1) | BR9916114A (en) |
| CA (1) | CA2354601A1 (en) |
| CZ (1) | CZ20012084A3 (en) |
| HK (1) | HK1043303A1 (en) |
| HU (1) | HUP0201618A3 (en) |
| IL (1) | IL143410A0 (en) |
| NO (1) | NO20012985L (en) |
| NZ (1) | NZ511790A (en) |
| PL (1) | PL354920A1 (en) |
| SK (1) | SK8262001A3 (en) |
| TR (1) | TR200101719T2 (en) |
| TW (1) | TW577740B (en) |
| WO (1) | WO2000035457A1 (en) |
| ZA (1) | ZA200104146B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| BR0005797A (en) * | 2000-03-20 | 2001-10-16 | Abbott Lab | Methods for the treatment of sexual dysfunction with apomorphine at specified plasma concentration levels |
| EP1345608B1 (en) * | 2000-11-22 | 2007-04-04 | Abbott Laboratories | Selective dopamine d4 receptor agonists for treating sexual dysfunction |
| NZ527113A (en) * | 2001-02-08 | 2005-04-29 | Pharmacia Corp | Rapid-onset medicament for the treatment of sexual dysfunction |
| JP2005526790A (en) * | 2002-03-19 | 2005-09-08 | ミシェル ホリック | Apomorphine and analog glycosides and orthoester glycoside derivatives, and methods of use thereof |
| SE0202365D0 (en) | 2002-08-05 | 2002-08-05 | Pharmacia Ab | New formulation and use thereof |
| US20040204439A1 (en) * | 2003-04-14 | 2004-10-14 | Staniforth John Nicholas | Composition, device, and method for treating sexual dysfunction via inhalation |
| WO2004089374A1 (en) * | 2003-04-14 | 2004-10-21 | Vectura Ltd | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation |
| JP2007532670A (en) | 2004-04-13 | 2007-11-15 | ザ マクレーン ホスピタル コーポレーション | R (-)-11-hydroxyaporphine derivative and method of using the same |
| GB2437488A (en) * | 2006-04-25 | 2007-10-31 | Optinose As | Pharmaceutical oily formulation for nasal or buccal administration |
| WO2009009083A1 (en) * | 2007-07-12 | 2009-01-15 | The Mclean Hospital Corporation | R(-)-2-methoxy-11-hydroxyaporphine and derivatives thereof |
| BRPI0800596A2 (en) | 2008-01-31 | 2009-09-22 | Univ Minas Gerais | method for potentiation of erectile function through the use of pharmaceutical compositions of the toxin tx2-6 from the phoneutria nigriventer spider |
| CA2821756C (en) | 2010-12-16 | 2021-06-29 | Cynapsus Therapeutics, Inc. | Sublingual films comprising apomorphine and an organic base |
| KR101374500B1 (en) * | 2012-10-09 | 2014-03-13 | 울산대학교 산학협력단 | Parmaceutical composition for preventing or treating cancer containing r(-)-propylnorapomorphine |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| ES2702174T3 (en) | 2013-04-05 | 2019-02-27 | Boehringer Ingelheim Int | Therapeutic uses of empagliflozin |
| MX2021004308A (en) | 2013-04-18 | 2022-10-26 | Boehringer Ingelheim Int | Pharmaceutical composition, methods for treating and uses thereof. |
| EP3288561B1 (en) * | 2015-04-30 | 2021-03-31 | Boehringer Ingelheim International GmbH | Methods and pharmaceutical compositions comprising a sglt2 inhibitor for treating or improving erectile dysfunction |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| CN112955967A (en) * | 2018-06-14 | 2021-06-11 | 阿斯利康(英国)有限公司 | Method for treating erectile dysfunction using pharmaceutical compositions of CGMP-specific phosphodiesterase 5 inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256652A (en) | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
| US5270323A (en) | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
| US5292520A (en) | 1990-09-13 | 1994-03-08 | Akzo N.V. | Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer |
| DE69434304T2 (en) | 1993-03-26 | 2005-12-29 | Merkus, Franciscus Wilhelmus H.M. | Pharmaceutical compositions for the intranasal administration of dihydroergotamine |
| CA2188385C (en) * | 1994-04-22 | 2000-07-11 | Ragab El-Rashidy | Dosage forms and method for ameliorating male erectile dysfunction |
| US5562917A (en) | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
| US5888534A (en) | 1995-06-13 | 1999-03-30 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5624677A (en) * | 1995-06-13 | 1997-04-29 | Pentech Pharmaceuticals, Inc. | Controlled release of drugs delivered by sublingual or buccal administration |
| US5688499A (en) | 1996-03-13 | 1997-11-18 | Queen's University At Kingston | Antagonism of endothelin actions |
| DE19652268C2 (en) | 1996-12-16 | 2000-06-29 | Lohmann Therapie Syst Lts | Medicinal preparation for the release of apomorphine in the oral cavity |
-
1998
- 1998-12-17 US US09/213,567 patent/US6291471B1/en not_active Expired - Fee Related
-
1999
- 1999-12-13 IL IL14341099A patent/IL143410A0/en unknown
- 1999-12-13 CN CN99814559A patent/CN1335772A/en active Pending
- 1999-12-13 AU AU21758/00A patent/AU2175800A/en not_active Abandoned
- 1999-12-13 NZ NZ511790A patent/NZ511790A/en unknown
- 1999-12-13 EP EP99966147A patent/EP1140094A1/en not_active Withdrawn
- 1999-12-13 WO PCT/US1999/029449 patent/WO2000035457A1/en not_active Application Discontinuation
- 1999-12-13 TR TR2001/01719T patent/TR200101719T2/en unknown
- 1999-12-13 SK SK826-2001A patent/SK8262001A3/en unknown
- 1999-12-13 JP JP2000587777A patent/JP2003521462A/en not_active Withdrawn
- 1999-12-13 KR KR1020017007500A patent/KR20010101241A/en not_active Application Discontinuation
- 1999-12-13 HU HU0201618A patent/HUP0201618A3/en unknown
- 1999-12-13 CA CA002354601A patent/CA2354601A1/en not_active Abandoned
- 1999-12-13 BR BR9916114-1A patent/BR9916114A/en not_active IP Right Cessation
- 1999-12-13 CZ CZ20012084A patent/CZ20012084A3/en unknown
- 1999-12-13 PL PL99354920A patent/PL354920A1/en not_active Application Discontinuation
- 1999-12-17 AR ARP990106551A patent/AR021912A1/en not_active Application Discontinuation
-
2000
- 2000-01-11 TW TW088122257A patent/TW577740B/en not_active IP Right Cessation
-
2001
- 2001-05-21 ZA ZA200104146A patent/ZA200104146B/en unknown
- 2001-06-15 NO NO20012985A patent/NO20012985L/en not_active Application Discontinuation
- 2001-07-03 BG BG105664A patent/BG105664A/en unknown
-
2002
- 2002-03-28 HK HK02102415.1A patent/HK1043303A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0201618A2 (en) | 2002-09-28 |
| CN1335772A (en) | 2002-02-13 |
| BG105664A (en) | 2002-02-28 |
| NO20012985L (en) | 2001-08-16 |
| BR9916114A (en) | 2003-01-14 |
| WO2000035457A1 (en) | 2000-06-22 |
| SK8262001A3 (en) | 2002-01-07 |
| HK1043303A1 (en) | 2002-09-13 |
| EP1140094A1 (en) | 2001-10-10 |
| HUP0201618A3 (en) | 2003-03-28 |
| JP2003521462A (en) | 2003-07-15 |
| CZ20012084A3 (en) | 2002-01-16 |
| AU2175800A (en) | 2000-07-03 |
| NZ511790A (en) | 2004-04-30 |
| PL354920A1 (en) | 2004-03-22 |
| KR20010101241A (en) | 2001-11-14 |
| US6291471B1 (en) | 2001-09-18 |
| TW577740B (en) | 2004-03-01 |
| ZA200104146B (en) | 2002-08-21 |
| IL143410A0 (en) | 2002-04-21 |
| AR021912A1 (en) | 2002-09-04 |
| TR200101719T2 (en) | 2002-08-21 |
| NO20012985D0 (en) | 2001-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6291471B1 (en) | Use of apomorphine for the treatment of organic erectile dysfunction in males | |
| US6756407B2 (en) | Method and compositions for the treatment or amelioration of female sexual dysfunction | |
| US6087362A (en) | Apomorphine and sildenafil composition | |
| AU752928B2 (en) | Treatment of female sexual dysfunction | |
| EP0954314B1 (en) | Dosage forms for ameliorating male erectile dysfunction | |
| EP0758895A1 (en) | Dosage forms and method for ameliorating male erectile dysfunction | |
| MXPA01012877A (en) | Nasal delivery of apomorphine. | |
| US6548510B1 (en) | Pharmaceutical composition containing deoxypeganine for the treatment of nicotine dependence | |
| US20020165122A1 (en) | Method and compositions for the treatment or amelioration of female sexual dysfunction | |
| AU4254799A (en) | Method and compositions for the treatment or amelioration of female sexual dysfunction | |
| JP2969509B2 (en) | Hypnotic composition | |
| AU2005201509A1 (en) | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males | |
| MXPA01006105A (en) | Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |